These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 11552716)

  • 21. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB; Zielinski CC
    Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook.
    Hudelist G; Köstler W; Czerwenka K; Kubista E; Singer CF
    Methods Find Exp Clin Pharmacol; 2004 Apr; 26(3):201-10. PubMed ID: 15148526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab: designer drug or fashionable fad?
    Freebairn AJ; Last AJ; Illidg TM
    Clin Oncol (R Coll Radiol); 2001; 13(6):427-33. PubMed ID: 11824879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
    Hudelist G; Köstler WJ; Attems J; Czerwenka K; Müller R; Manavi M; Steger GG; Kubista E; Zielinski CC; Singer CF
    Br J Cancer; 2003 Sep; 89(6):983-91. PubMed ID: 12966413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy.
    Gatta LB; Incardona P; Cadei M; Grigolato P; Simoncelli S; Balzarini P
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):413-20. PubMed ID: 22417857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2/neu testing in breast cancer.
    Ross JS; Fletcher JA; Bloom KJ; Linette GP; Stec J; Clark E; Ayers M; Symmans WF; Pusztai L; Hortobagyi GN
    Am J Clin Pathol; 2003 Dec; 120 Suppl():S53-71. PubMed ID: 15298144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer.
    Sahin AA
    Adv Anat Pathol; 2000 May; 7(3):158-66. PubMed ID: 10809222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H; Azim HA
    Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
    Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
    Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2/neu as a predictive marker of response to breast cancer therapy.
    Pegram MD; Pauletti G; Slamon DJ
    Breast Cancer Res Treat; 1998; 52(1-3):65-77. PubMed ID: 10066073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.